Cantor Fitzgerald Forecasts EPRX FY2025 Earnings

Key Points

• Cantor Fitzgerald has projected that Eupraxia Pharmaceuticals Inc. will report FY2025 earnings of ($0.63) per share, slightly better than the consensus estimate of ($0.67) per share.
• The stock currently has an Overweight rating with a target price of $11.00, following positive ratings from multiple analysts.
• Eupraxia Pharmaceuticals' stock is trading at $5.49 with a market cap of $197.42 million, down 0.9% recently, and has experienced a range between $2.20 and $6.20 over the past year.

Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX - Free Report) - Analysts at Cantor Fitzgerald issued their FY2025 earnings per share estimates for shares of Eupraxia Pharmaceuticals in a research note issued on Thursday, July 24th. Cantor Fitzgerald analyst K. Kluska anticipates that the company will earn ($0.63) per share for the year. Cantor Fitzgerald currently has a "Overweight" rating and a $11.00 target price on the stock. The consensus estimate for Eupraxia Pharmaceuticals' current full-year earnings is ($0.67) per share. Cantor Fitzgerald also issued estimates for Eupraxia Pharmaceuticals' FY2026 earnings at ($0.64) EPS.

Eupraxia Pharmaceuticals (NASDAQ:EPRX - Get Free Report) last posted its quarterly earnings data on Tuesday, May 6th. The company reported ($0.21) earnings per share for the quarter, missing analysts' consensus estimates of ($0.19) by ($0.02).

A number of other analysts have also commented on EPRX. HC Wainwright initiated coverage on Eupraxia Pharmaceuticals in a report on Thursday, June 26th. They issued a "buy" rating and a $12.00 target price for the company. Canaccord Genuity Group initiated coverage on Eupraxia Pharmaceuticals in a report on Monday, June 16th. They issued a "speculative buy" rating for the company. Five analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock has an average rating of "Buy" and a consensus target price of $11.00.

Eupraxia Pharmaceuticals Trading Down 0.9%

Eupraxia Pharmaceuticals stock opened at $5.49 on Monday. The firm has a market cap of $197.42 million, a price-to-earnings ratio of -7.22 and a beta of 1.55. The stock has a fifty day simple moving average of $4.63 and a two-hundred day simple moving average of $3.89. Eupraxia Pharmaceuticals has a 12 month low of $2.20 and a 12 month high of $6.20.

Hedge Funds Weigh In On Eupraxia Pharmaceuticals

A number of institutional investors and hedge funds have recently modified their holdings of EPRX. Raymond James Financial Inc. purchased a new position in shares of Eupraxia Pharmaceuticals in the 4th quarter worth $37,000. Bank of Montreal Can lifted its position in Eupraxia Pharmaceuticals by 15.2% during the fourth quarter. Bank of Montreal Can now owns 56,750 shares of the company's stock valued at $178,000 after purchasing an additional 7,500 shares in the last quarter. Millennium Management LLC purchased a new position in Eupraxia Pharmaceuticals during the fourth quarter valued at $31,000. Scotia Capital Inc. lifted its position in Eupraxia Pharmaceuticals by 11.6% during the first quarter. Scotia Capital Inc. now owns 1,552,679 shares of the company's stock valued at $5,072,000 after purchasing an additional 160,960 shares in the last quarter. Finally, Royal Bank of Canada lifted its position in Eupraxia Pharmaceuticals by 21.1% during the first quarter. Royal Bank of Canada now owns 342,828 shares of the company's stock valued at $1,125,000 after purchasing an additional 59,683 shares in the last quarter.

Eupraxia Pharmaceuticals Company Profile

Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company. It focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. Th company's lead product candidate includes EP-104IAR, for the treatment of pain due to osteoarthritis of the knee.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.